Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic target for managing metabolic disorders. These naturally occurring molecules are secreted by the gut in response to food intake, stimulating insulin secretion and suppressing glucagon output. GLP-1 derivatives exhibit promising therapeutic efficacy in treating type 2